CCR5 and metabolic dysfunction-associated steatohepatitis: Cenicriviroc, the dual antagonist of C-C chemokine receptor (CCR)2/CCR5 pathways in NASH-mediated inflammation and fibrosis, is currently being under phase III clinical trials for NASH patients with fibrosis (ClinicalTrials.gov Identifier: NCT03028740) [58].